The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies

Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting multiple sclerosis (MS). The objective of this post hoc analysis of the phase 3, pooled TEMSO (NCT00134563) and TOWER (NCT00751881) dataset is to evaluate the effect of teriflunomide treatment on annualised relapse r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mult Scler
Hauptverfasser: Freedman, Mark S, Wolinsky, Jerry S, Comi, Giancarlo, Kappos, Ludwig, Olsson, Tomas P, Miller, Aaron E, Thangavelu, Karthinathan, Benamor, Myriam, Truffinet, Philippe, O’Connor, Paul W
Format: Artigo
Sprache:Inglês
Veröffentlicht: SAGE Publications 2017
Schlagworte:
Short Reports
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5891690/
https://ncbi.nlm.nih.gov/pubmed/28304217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458517695468
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge